array(40) {
  [0]=>
  string(4) "1553"
  ["article_id"]=>
  string(4) "1553"
  [1]=>
  string(50) "Boots buys tech firm to boost its online provision"
  ["article_title"]=>
  string(50) "Boots buys tech firm to boost its online provision"
  [2]=>
  string(150) "The pharmacy chain Boots has bought a health technology company that it says will allow patients to order prescriptions online by linking with their G"
  ["short_description"]=>
  string(150) "The pharmacy chain Boots has bought a health technology company that it says will allow patients to order prescriptions online by linking with their G"
  [3]=>
  string(160) "The pharmacy chain Boots has bought a health technology company that it says will allow patients to order prescriptions online by linking with their GP records."
  ["description"]=>
  string(160) "The pharmacy chain Boots has bought a health technology company that it says will allow patients to order prescriptions online by linking with their GP records."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "11"
  ["rss_id"]=>
  string(2) "11"
  [14]=>
  string(138) "https://www.pharmaceutical-journal.com/news-and-analysis/news-in-brief/boots-buys-tech-firm-to-boost-its-online-provision/20205965.article"
  ["blog_url"]=>
  string(138) "https://www.pharmaceutical-journal.com/news-and-analysis/news-in-brief/boots-buys-tech-firm-to-boost-its-online-provision/20205965.article"
  [15]=>
  string(19) "2019-01-09 00:53:00"
  ["add_date"]=>
  string(19) "2019-01-09 00:53:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-01-15 18:25:21"
  ["create_at"]=>
  string(19) "2019-01-15 18:25:21"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2411"
  ["article_id"]=>
  string(4) "2411"
  [1]=>
  string(132) "European Commission publishes factsheet on medical devices and in vitro medical devices for non-EU and non-EEA competent authorities"
  ["article_title"]=>
  string(132) "European Commission publishes factsheet on medical devices and in vitro medical devices for non-EU and non-EEA competent authorities"
  [2]=>
  string(150) "Introduction The European Commission has published a factsheet addressed to competent authorities of third countries. This factsheet is one of several"
  ["short_description"]=>
  string(150) "Introduction The European Commission has published a factsheet addressed to competent authorities of third countries. This factsheet is one of several"
  [3]=>
  string(883) "
Introduction The European Commission has published a factsheet addressed to competent authorities of third countries. This factsheet is one of several guidance documents published by the European Commission to clarify points and answer questions regarding the implications of the Medical Device Regulation (MDR) and the In Vitro Medical Device Regulation (IVDR). The factsheet is intended
&#nl
The post European Commission publishes factsheet on medical devices and in vitro medical devices for non-EU and non-EEA competent authorities appeared first on Focus on Regulation.
&#nl"
  ["description"]=>
  string(883) "
Introduction The European Commission has published a factsheet addressed to competent authorities of third countries. This factsheet is one of several guidance documents published by the European Commission to clarify points and answer questions regarding the implications of the Medical Device Regulation (MDR) and the In Vitro Medical Device Regulation (IVDR). The factsheet is intended
&#nl
The post European Commission publishes factsheet on medical devices and in vitro medical devices for non-EU and non-EEA competent authorities appeared first on Focus on Regulation.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(3) "101"
  ["rss_id"]=>
  string(3) "101"
  [14]=>
  string(173) "https://www.hlregulation.com/2019/01/08/european-commission-publishes-factsheet-on-medical-devices-and-in-vitro-medical-devices-for-non-eu-and-non-eea-competent-authorities/"
  ["blog_url"]=>
  string(173) "https://www.hlregulation.com/2019/01/08/european-commission-publishes-factsheet-on-medical-devices-and-in-vitro-medical-devices-for-non-eu-and-non-eea-competent-authorities/"
  [15]=>
  string(19) "2019-01-08 19:31:05"
  ["add_date"]=>
  string(19) "2019-01-08 19:31:05"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:42:28"
  ["create_at"]=>
  string(19) "2019-05-09 16:42:28"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1558"
  ["article_id"]=>
  string(4) "1558"
  [1]=>
  string(168) "Novartis Investigational Therapy Crizanlizumab (SEG101) Receives FDA Breakthrough Therapy Designation for the Prevention of Vaso-Occlusive Crises in Sickle Cell Disease"
  ["article_title"]=>
  string(168) "Novartis Investigational Therapy Crizanlizumab (SEG101) Receives FDA Breakthrough Therapy Designation for the Prevention of Vaso-Occlusive Crises in Sickle Cell Disease"
  [2]=>
  string(150) "Basel, January 8, 2019 - Novartis announced today that the US Food and Drug Administration (FDA) has granted crizanlizumab (SEG101) Breakthrough Thera"
  ["short_description"]=>
  string(150) "Basel, January 8, 2019 - Novartis announced today that the US Food and Drug Administration (FDA) has granted crizanlizumab (SEG101) Breakthrough Thera"
  [3]=>
  string(252) "Basel, January 8, 2019 - Novartis announced today that the US Food and Drug Administration (FDA) has granted crizanlizumab (SEG101) Breakthrough Therapy designation for the prevention of vaso-occlusive crises (VOCs) in patients of all genotypes with..."
  ["description"]=>
  string(252) "Basel, January 8, 2019 - Novartis announced today that the US Food and Drug Administration (FDA) has granted crizanlizumab (SEG101) Breakthrough Therapy designation for the prevention of vaso-occlusive crises (VOCs) in patients of all genotypes with..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(300) "https://www.drugs.com/clinical_trials/novartis-investigational-therapy-crizanlizumab-seg101-receives-fda-breakthrough-therapy-designation-18053.html?utm_source=ddc&utm_medium=rss&utm_campaign=Novartis+Investigational+Therapy+Crizanlizumab+%28SEG101%29+Receives+FDA+Breakthrough+Therapy+Designation+fo"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/clinical_trials/novartis-investigational-therapy-crizanlizumab-seg101-receives-fda-breakthrough-therapy-designation-18053.html?utm_source=ddc&utm_medium=rss&utm_campaign=Novartis+Investigational+Therapy+Crizanlizumab+%28SEG101%29+Receives+FDA+Breakthrough+Therapy+Designation+fo"
  [15]=>
  string(19) "2019-01-08 13:01:22"
  ["add_date"]=>
  string(19) "2019-01-08 13:01:22"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-01-15 18:25:23"
  ["create_at"]=>
  string(19) "2019-01-15 18:25:23"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1559"
  ["article_id"]=>
  string(4) "1559"
  [1]=>
  string(103) "MediciNova Announces Initiation of Enrollment in a Clinical Trial of MN-166 (ibudilast) in Glioblastoma"
  ["article_title"]=>
  string(103) "MediciNova Announces Initiation of Enrollment in a Clinical Trial of MN-166 (ibudilast) in Glioblastoma"
  [2]=>
  string(150) "LA JOLLA, Calif., Jan. 08, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and"
  ["short_description"]=>
  string(150) "LA JOLLA, Calif., Jan. 08, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and"
  [3]=>
  string(251) "LA JOLLA, Calif., Jan. 08, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the first..."
  ["description"]=>
  string(251) "LA JOLLA, Calif., Jan. 08, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the first..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(287) "https://www.drugs.com/clinical_trials/medicinova-announces-initiation-enrollment-clinical-trial-mn-166-ibudilast-glioblastoma-18054.html?utm_source=ddc&utm_medium=rss&utm_campaign=MediciNova+Announces+Initiation+of+Enrollment+in+a+Clinical+Trial+of+MN-166+%28ibudilast%29+in+Glioblastoma"
  ["blog_url"]=>
  string(287) "https://www.drugs.com/clinical_trials/medicinova-announces-initiation-enrollment-clinical-trial-mn-166-ibudilast-glioblastoma-18054.html?utm_source=ddc&utm_medium=rss&utm_campaign=MediciNova+Announces+Initiation+of+Enrollment+in+a+Clinical+Trial+of+MN-166+%28ibudilast%29+in+Glioblastoma"
  [15]=>
  string(19) "2019-01-08 13:01:01"
  ["add_date"]=>
  string(19) "2019-01-08 13:01:01"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-01-15 18:25:23"
  ["create_at"]=>
  string(19) "2019-01-15 18:25:23"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "4538"
  ["article_id"]=>
  string(4) "4538"
  [1]=>
  string(30) "New Medical Device Legislation"
  ["article_title"]=>
  string(30) "New Medical Device Legislation"
  [2]=>
  string(156) "Course overview&#nl&#nlThe New Medical Device Regulation (MDR) brings about a period of great change, uncertainty and opportunity within the medical technol"
  ["short_description"]=>
  string(156) "Course overview&#nl&#nlThe New Medical Device Regulation (MDR) brings about a period of great change, uncertainty and opportunity within the medical technol"
  [3]=>
  string(506) "Course overview&#nl&#nlThe New Medical Device Regulation (MDR) brings about a period of great change, uncertainty and opportunity within the medical technology and diagnostics sectors. This seminar will help you embrace these changes and operate successfully in the new environment in Europe. It will cover in depth the new regulations and their implementation by the Member States and Notified Bodies. You will get to hear the latest thoughts on clinical development, safety monitoring and the implicat..."
  ["description"]=>
  string(506) "Course overview&#nl&#nlThe New Medical Device Regulation (MDR) brings about a period of great change, uncertainty and opportunity within the medical technology and diagnostics sectors. This seminar will help you embrace these changes and operate successfully in the new environment in Europe. It will cover in depth the new regulations and their implementation by the Member States and Notified Bodies. You will get to hear the latest thoughts on clinical development, safety monitoring and the implicat..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(62) "https://www.pharmiweb.com/event/new-medical-device-legislation"
  ["blog_url"]=>
  string(62) "https://www.pharmiweb.com/event/new-medical-device-legislation"
  [15]=>
  string(19) "2019-01-08 12:52:54"
  ["add_date"]=>
  string(19) "2019-01-08 12:52:54"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-09-14 14:32:21"
  ["create_at"]=>
  string(19) "2019-09-14 14:32:21"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "4537"
  ["article_id"]=>
  string(4) "4537"
  [1]=>
  string(56) "GCP and Clinical Research Update - Hot Inspection Topics"
  ["article_title"]=>
  string(56) "GCP and Clinical Research Update - Hot Inspection Topics"
  [2]=>
  string(156) "Course overview&#nl&#nlClinical research is a constantly evolving field and the regulatory requirements are regularly being updated. In order to stay up to "
  ["short_description"]=>
  string(156) "Course overview&#nl&#nlClinical research is a constantly evolving field and the regulatory requirements are regularly being updated. In order to stay up to "
  [3]=>
  string(512) "Course overview&#nl&#nlClinical research is a constantly evolving field and the regulatory requirements are regularly being updated. In order to stay up to date and maintain your GCP knowledge, it is important to receive regular training.&#nl&#nlThis course provides an update on recent changes to relevant legislation and guidance and will discuss how these changes have been implemented. Topics covered will include ICH GCP R2, the EU Clinical Trial Regulation, data integrity and the impact of GDPR on clin..."
  ["description"]=>
  string(512) "Course overview&#nl&#nlClinical research is a constantly evolving field and the regulatory requirements are regularly being updated. In order to stay up to date and maintain your GCP knowledge, it is important to receive regular training.&#nl&#nlThis course provides an update on recent changes to relevant legislation and guidance and will discuss how these changes have been implemented. Topics covered will include ICH GCP R2, the EU Clinical Trial Regulation, data integrity and the impact of GDPR on clin..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(86) "https://www.pharmiweb.com/event/gcp-and-clinical-research-update-hot-inspection-topics"
  ["blog_url"]=>
  string(86) "https://www.pharmiweb.com/event/gcp-and-clinical-research-update-hot-inspection-topics"
  [15]=>
  string(19) "2019-01-08 12:48:20"
  ["add_date"]=>
  string(19) "2019-01-08 12:48:20"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-09-14 14:32:21"
  ["create_at"]=>
  string(19) "2019-09-14 14:32:21"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "4536"
  ["article_id"]=>
  string(4) "4536"
  [1]=>
  string(37) "Effective Technical Writing & Editing"
  ["article_title"]=>
  string(37) "Effective Technical Writing & Editing"
  [2]=>
  string(156) "About this course&#nl&#nlThis interactive course will provide a practical guide to the foundations of effective technical writing and editing. With a combin"
  ["short_description"]=>
  string(156) "About this course&#nl&#nlThis interactive course will provide a practical guide to the foundations of effective technical writing and editing. With a combin"
  [3]=>
  string(518) "About this course&#nl&#nlThis interactive course will provide a practical guide to the foundations of effective technical writing and editing. With a combination of lectures, hands-on exercises and text review sessions, this course will enable you to improve your writing and editing skills, and apply them to your role in the workplace. &#nl&#nlWho should attend?&#nl&#nlThis course has been designed for all those writing or editing scientific and medical texts, as well as technical documents, including those wh..."
  ["description"]=>
  string(518) "About this course&#nl&#nlThis interactive course will provide a practical guide to the foundations of effective technical writing and editing. With a combination of lectures, hands-on exercises and text review sessions, this course will enable you to improve your writing and editing skills, and apply them to your role in the workplace. &#nl&#nlWho should attend?&#nl&#nlThis course has been designed for all those writing or editing scientific and medical texts, as well as technical documents, including those wh..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(69) "https://www.pharmiweb.com/event/effective-technical-writing-editing-1"
  ["blog_url"]=>
  string(69) "https://www.pharmiweb.com/event/effective-technical-writing-editing-1"
  [15]=>
  string(19) "2019-01-08 12:39:46"
  ["add_date"]=>
  string(19) "2019-01-08 12:39:46"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-09-14 14:32:21"
  ["create_at"]=>
  string(19) "2019-09-14 14:32:21"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "4547"
  ["article_id"]=>
  string(4) "4547"
  [1]=>
  string(36) "Risk Management in Clinical Research"
  ["article_title"]=>
  string(36) "Risk Management in Clinical Research"
  [2]=>
  string(156) "Course overview &#nl&#nlRisk management is becoming increasingly important to running clinical trials and ensuring compliance with regulatory expectations. "
  ["short_description"]=>
  string(156) "Course overview &#nl&#nlRisk management is becoming increasingly important to running clinical trials and ensuring compliance with regulatory expectations. "
  [3]=>
  string(512) "Course overview &#nl&#nlRisk management is becoming increasingly important to running clinical trials and ensuring compliance with regulatory expectations. There are now numerous pharmaceutical guidelines covering risk management including ICH Q9 and the revised ICH GCP R2 guideline.&#nl&#nlThis essential one-day course will explain the importance of using risk management techniques in clinical research to comply with the latest focus on inspection in this area. It will show you how risk management can i..."
  ["description"]=>
  string(512) "Course overview &#nl&#nlRisk management is becoming increasingly important to running clinical trials and ensuring compliance with regulatory expectations. There are now numerous pharmaceutical guidelines covering risk management including ICH Q9 and the revised ICH GCP R2 guideline.&#nl&#nlThis essential one-day course will explain the importance of using risk management techniques in clinical research to comply with the latest focus on inspection in this area. It will show you how risk management can i..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(68) "https://www.pharmiweb.com/event/risk-management-in-clinical-research"
  ["blog_url"]=>
  string(68) "https://www.pharmiweb.com/event/risk-management-in-clinical-research"
  [15]=>
  string(19) "2019-01-08 12:35:07"
  ["add_date"]=>
  string(19) "2019-01-08 12:35:07"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-09-14 14:32:21"
  ["create_at"]=>
  string(19) "2019-09-14 14:32:21"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "4549"
  ["article_id"]=>
  string(4) "4549"
  [1]=>
  string(36) "Regulatory Affairs for Support Staff"
  ["article_title"]=>
  string(36) "Regulatory Affairs for Support Staff"
  [2]=>
  string(156) "Course overview &#nl&#nlBy attending this course you will gain an overview of EU regulatory procedures required to register products in Europe and the regul"
  ["short_description"]=>
  string(156) "Course overview &#nl&#nlBy attending this course you will gain an overview of EU regulatory procedures required to register products in Europe and the regul"
  [3]=>
  string(505) "Course overview &#nl&#nlBy attending this course you will gain an overview of EU regulatory procedures required to register products in Europe and the regulatory activities that need to be complied with to keep products on the market.Pharmacovigilance and safety reporting will be covered as well as licence variations and the commercial aspects of pharmaceutical products. The potential impact of Brexit will also be discussed. The course will provide a thorough grounding in the subject of regulatory..."
  ["description"]=>
  string(505) "Course overview &#nl&#nlBy attending this course you will gain an overview of EU regulatory procedures required to register products in Europe and the regulatory activities that need to be complied with to keep products on the market.Pharmacovigilance and safety reporting will be covered as well as licence variations and the commercial aspects of pharmaceutical products. The potential impact of Brexit will also be discussed. The course will provide a thorough grounding in the subject of regulatory..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(70) "https://www.pharmiweb.com/event/regulatory-affairs-for-support-staff-1"
  ["blog_url"]=>
  string(70) "https://www.pharmiweb.com/event/regulatory-affairs-for-support-staff-1"
  [15]=>
  string(19) "2019-01-08 12:31:53"
  ["add_date"]=>
  string(19) "2019-01-08 12:31:53"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-09-14 14:32:21"
  ["create_at"]=>
  string(19) "2019-09-14 14:32:21"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1560"
  ["article_id"]=>
  string(4) "1560"
  [1]=>
  string(184) "UroGen Pharma Announces Positive Results of UGN-101 from Pivotal Phase 3 OLYMPUS Trial for the Non-Surgical Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC)"
  ["article_title"]=>
  string(184) "UroGen Pharma Announces Positive Results of UGN-101 from Pivotal Phase 3 OLYMPUS Trial for the Non-Surgical Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC)"
  [2]=>
  string(150) "NEW YORK--(BUSINESS WIRE)--Jan. 8, 2019-- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to addres"
  ["short_description"]=>
  string(150) "NEW YORK--(BUSINESS WIRE)--Jan. 8, 2019-- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to addres"
  [3]=>
  string(248) "NEW YORK--(BUSINESS WIRE)--Jan. 8, 2019-- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, today announced topline results from the ongoing pivotal..."
  ["description"]=>
  string(248) "NEW YORK--(BUSINESS WIRE)--Jan. 8, 2019-- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, today announced topline results from the ongoing pivotal..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(300) "https://www.drugs.com/clinical_trials/urogen-pharma-announces-positive-results-ugn-101-pivotal-phase-3-olympus-trial-non-surgical-18052.html?utm_source=ddc&utm_medium=rss&utm_campaign=UroGen+Pharma+Announces+Positive+Results+of+UGN-101+from+Pivotal+Phase+3+OLYMPUS+Trial+for+the+Non-Surgical+Treatmen"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/clinical_trials/urogen-pharma-announces-positive-results-ugn-101-pivotal-phase-3-olympus-trial-non-surgical-18052.html?utm_source=ddc&utm_medium=rss&utm_campaign=UroGen+Pharma+Announces+Positive+Results+of+UGN-101+from+Pivotal+Phase+3+OLYMPUS+Trial+for+the+Non-Surgical+Treatmen"
  [15]=>
  string(19) "2019-01-08 09:01:58"
  ["add_date"]=>
  string(19) "2019-01-08 09:01:58"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-01-15 18:25:23"
  ["create_at"]=>
  string(19) "2019-01-15 18:25:23"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1536"
  ["article_id"]=>
  string(4) "1536"
  [1]=>
  string(168) "Sun Pharmaceutical Industries, Inc. Issues Voluntary Nationwide Recall of Vecuronium Bromide for Injection Due to the Presence of Particulate Matter Identified as Glass"
  ["article_title"]=>
  string(168) "Sun Pharmaceutical Industries, Inc. Issues Voluntary Nationwide Recall of Vecuronium Bromide for Injection Due to the Presence of Particulate Matter Identified as Glass"
  [2]=>
  string(150) "Audience: Health Professional, Pharmacy Sun Pharmaceutical Industries, Inc. (SPII), a wholly owned subsidiary of Sun Pharmaceutical Industries, Ltd. i"
  ["short_description"]=>
  string(150) "Audience: Health Professional, Pharmacy Sun Pharmaceutical Industries, Inc. (SPII), a wholly owned subsidiary of Sun Pharmaceutical Industries, Ltd. i"
  [3]=>
  string(252) "Audience: Health Professional, Pharmacy Sun Pharmaceutical Industries, Inc. (SPII), a wholly owned subsidiary of Sun Pharmaceutical Industries, Ltd. is voluntarily recalling three lots of Vecuronium Bromide for Injection, 10 mg (lyophilized powder),..."
  ["description"]=>
  string(252) "Audience: Health Professional, Pharmacy Sun Pharmaceutical Industries, Inc. (SPII), a wholly owned subsidiary of Sun Pharmaceutical Industries, Ltd. is voluntarily recalling three lots of Vecuronium Bromide for Injection, 10 mg (lyophilized powder),..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "7"
  ["rss_id"]=>
  string(1) "7"
  [14]=>
  string(300) "https://www.drugs.com/fda/sun-pharmaceutical-industries-inc-issues-voluntary-nationwide-recall-vecuronium-bromide-due-14234.html?utm_source=ddc&utm_medium=rss&utm_campaign=Sun+Pharmaceutical+Industries%2C+Inc.+Issues+Voluntary+Nationwide+Recall+of+Vecuronium+Bromide+for+Injection+Due+to+the+Presence"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/fda/sun-pharmaceutical-industries-inc-issues-voluntary-nationwide-recall-vecuronium-bromide-due-14234.html?utm_source=ddc&utm_medium=rss&utm_campaign=Sun+Pharmaceutical+Industries%2C+Inc.+Issues+Voluntary+Nationwide+Recall+of+Vecuronium+Bromide+for+Injection+Due+to+the+Presence"
  [15]=>
  string(19) "2019-01-08 08:00:00"
  ["add_date"]=>
  string(19) "2019-01-08 08:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-01-15 18:25:20"
  ["create_at"]=>
  string(19) "2019-01-15 18:25:20"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1537"
  ["article_id"]=>
  string(4) "1537"
  [1]=>
  string(156) "KemPharm Announces FDA Approval of sNDA for Two Additional Strengths of Apadaz (4.08 mg benzhydrocodone/325 mg APAP and 8.16 mg benzhydrocodone/325 mg APAP)"
  ["article_title"]=>
  string(156) "KemPharm Announces FDA Approval of sNDA for Two Additional Strengths of Apadaz (4.08 mg benzhydrocodone/325 mg APAP and 8.16 mg benzhydrocodone/325 mg APAP)"
  [2]=>
  string(150) "CORALVILLE, Iowa, Jan. 07, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and deve"
  ["short_description"]=>
  string(150) "CORALVILLE, Iowa, Jan. 07, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and deve"
  [3]=>
  string(250) "CORALVILLE, Iowa, Jan. 07, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that the U.S. Food and Drug Administration (FDA)..."
  ["description"]=>
  string(250) "CORALVILLE, Iowa, Jan. 07, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that the U.S. Food and Drug Administration (FDA)..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "8"
  ["rss_id"]=>
  string(1) "8"
  [14]=>
  string(300) "https://www.drugs.com/newdrugs/kempharm-announces-fda-approval-snda-two-additional-apadaz-4-08-mg-benzhydrocodone-325-mg-apap-8-16-4900.html?utm_source=ddc&utm_medium=rss&utm_campaign=KemPharm+Announces+FDA+Approval+of+sNDA+for+Two+Additional+Strengths+of+Apadaz+%284.08+mg+benzhydrocodone%2F325+mg+A"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/newdrugs/kempharm-announces-fda-approval-snda-two-additional-apadaz-4-08-mg-benzhydrocodone-325-mg-apap-8-16-4900.html?utm_source=ddc&utm_medium=rss&utm_campaign=KemPharm+Announces+FDA+Approval+of+sNDA+for+Two+Additional+Strengths+of+Apadaz+%284.08+mg+benzhydrocodone%2F325+mg+A"
  [15]=>
  string(19) "2019-01-08 07:01:08"
  ["add_date"]=>
  string(19) "2019-01-08 07:01:08"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-01-15 18:25:20"
  ["create_at"]=>
  string(19) "2019-01-15 18:25:20"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}